Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in Alzheimer's disease
NCT00814801Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2007
- Primary completion
- Sep 2008
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of galantamine in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Feb 2007; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00814801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00814801.